Navigation Links
Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
Date:9/2/2007

A nanoparticle drug delivery system designed for brain tumour therapy has shown promising tumour cell selectivity in a novel cell culture model devised by scientists at The University of Nottingham. The project, conducted jointly by the Schools of Pharmacy, Biomedical Sciences and Human Development, will be featured in the September issue of the Experimental Biology and Medicine.

Therapy for brain cancers is particularly difficult for a number of reasons, including getting sufficient drug to the tumour and selectivity of drug action. Dr Martin Garnett, Associate Professor of drug delivery at the School of Pharmacy said: We are working on a number of new therapeutic approaches using nanoparticle drug delivery systems. However, understanding and developing these systems requires suitable models for their evaluation.

The nanoparticles used in this study were prepared from a novel biodegradable polymer poly (glycerol adipate). The polymer has been further modified to enhance incorporation of drugs and make the nanoparticles more effective.

Dr Terence Parker, Associate Professor in the School of Biomedical Sciences explained: The interaction of tumour cells with brain cells varies between different tumours and different locations within the brain. Using 3-dimensional culture models is therefore important in ensuring that the behaviour of cells in culture is similar to that seen in real life.

The work was mainly carried out by graduate student Weina Meng who formulated the fluorescently labelled nanoparticles and studied them in a variety of tumour and brain cell cultures. Her early studies showed faster uptake of nanoparticles into tumour cell cultures than normal brain cell cultures grown separately. This selectivity was only seen in 3-dimensional cultures and was the driving force to develop a more complex and representative model.

Tumour cell aggregates have been used as cell culture models of cancer cells for many years. Similarly thin brain slices from newborn rats can be cultured for weeks and are an important tool in brain biology. In the cell co-culture model now reported, these two techniques have been brought together for the first time. Brain tumour cell aggregates were labelled with fluorescent iron microparticles and grown on normal newborn rat-brain tissue slices. The double cell labelling technique allowed investigation of tumour cell invasion into brain tissue by either fluorescence or electron microscopy from the same samples. Using these techniques the tumour aggregates were found to invade the brain slices in a similar manner to tumours in the body. Having developed the model then the tumour selective uptake of nanoparticles was demonstrated in the co-culture.

The collaboration on this project has been nurtured by Professor David Walker of the School of Human Development who co-founded the Childrens Brain Tumour Research Group at Nottingham. Professor Walker said: Understanding the biology of tumours is important if we are to develop effective new treatments. This work demonstrates how close co-operation between disciplines can help to push forward ideas which could lead to new clinical therapies.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, agrees with Professor Walker. Dr. Goodman stated: The convergence of cancer cell biology and nanoscience, exemplified by this study, holds great promise for the future of brain tumour therapy.


'/>"/>
Contact: Dr Martin Garnett
44-011-595-15045
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel antibiotic dressing developed for improved wound healing
3. A novel augmentation
4. Novel biopsy technique for prostate cancer
5. Novel computer model for breast cancer
6. Novel research on liver cancer
7. Novel way to fight cancer
8. Novel test for bowel cancer
9. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
10. Novel Therapy for Chronic Problem
11. Gene enchances radiation therapy - A novel approach to fight cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: